Gene therapy fault puts medtech under spotlight:
This article was originally published in Clinica
Executive Summary
Italy, France, Germany and the US have temporarily halted gene therapy trials, after a French patient being treated for x-linked severe combined immunodeficiency (X-SCID) developed leukaemia. The UK, however, has stopped short of halting such research, in the belief that the benefits far outweigh the risks. In early 2000, the US FDA halted an angiogenesis trial using vascular endothelial growth-factor 2 (VEGF-2), after Vascular Genetics delayed reporting the death of two patients (see Clinica No 899, p 22). The scientific community, however, gave unqualified support for the safety and potential efficacy of gene therapy (see Clinica No 900, p 15). Worldwide there are 636 completed, ongoing or pending gene therapy trials, used to treat a range of conditions, from advanced breast cancer to coronary heart disease.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.